98%
921
2 minutes
20
The incorporation of fluorinated amino acids into proteins through natural biosynthesis in E. coli often leads to the production of heterogeneous fluorinated proteins. The stabilities of proteins with different F labelling states can vary, but these differences are challenging to measure due to the difficulty in separating the fluorinated protein mixtures that differ by only a few F atoms. Here, we simultaneously incorporated both fluoro-phenylalanines (3-fluoro-phenylalanine, 3FF; or 4-fluoro-phenylalanine, 4FF) and 5-fluoro-tryptophan (5FW) into GB1 protein. We are able to measure the stability of GB1 protein with different F labelling states without the need for sample separation by taking the advantage of F NMR. The results showed that 4FF-5FW-GB1 with varying F labelling states exhibited significantly different protein stability, with higher 4FF labeling efficiency correlating with decreased stability. Furthermore, residues F and F show synergistic effects on GB1 stability. In contrast, the 3FF and 5FW substitution exhibits a slightly stabilizing effect on GB1 stability. The present research provides a convenient F NMR method to simultaneously measure fluorine labelling effects on protein stability, favouring precise understanding and analysis of fluorine labelling effects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.talanta.2025.127959 | DOI Listing |
J Labelled Comp Radiopharm
September 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Departmen
A peptide-based, hypoxia-inducible factor-1 α (HIF-1α) specific PET tracer for tumor hypoxia imaging is reported. It was prepared with a rapid AlF labeling method with high stability. AlF-CLLFVY specifically binds to HIF-1α with high affinity and shows higher uptake in cells under hypoxia.
View Article and Find Full Text PDFJ Comput Aided Mol Des
September 2025
Department of Medical Physics and Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv, 61022, Ukraine.
Fluorine-18-labeled radiopharmaceuticals are central to PET-based oncology imaging, yet comparative evaluations of their mechanistic behavior and diagnostic potential remain fragmented. In this study, we present a multidimensional in silico framework integrating pharmacokinetic modeling, structural ADMET prediction, and unsupervised clustering to systematically evaluate five widely used F-labeled PET radiopharmaceuticals: [F]FDG, [F]FET, [F]DOPA, [F]FMISO, and [F]FLT. Each radiopharmaceutical was simulated using a harmonized three-compartment model in COPASI to capture uptake dynamics under both normal and pathological conditions.
View Article and Find Full Text PDFQuant Imaging Med Surg
September 2025
Department of Nuclear Medicine, Institute of Traditional Chinese Medicine of Sichuan Academy of Chinese Medicine Sciences (Sichuan Second Hospital of Traditional Chinese Medicine), Chengdu, China.
Background: Bone metastases of lung cancer typically indicate disease progression and poor prognosis. Early and accurate detection is crucial for staging, treatment planning, and prognostic evaluation. This study aimed to compare the diagnostic value of gallium 68-labeled fibroblast-activation protein inhibitor-04 ([Ga]Ga-FAPI-04) and fluorine 18-labeled fluorodeoxyglucose ([F]FDG) positron-emission tomography/computed tomography (PET/CT) imaging in detecting bone metastases in lung cancer.
View Article and Find Full Text PDFEur J Med Chem
December 2025
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Straße, Jülich, 52428, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Radiochemistry and Experimental Molecular Imaging, Kerpener Str
Fibroblast activation protein (FAP) is almost exclusively expressed on cancer-associated stromal cells, making it a promising target for tumor imaging by positron emission tomography (PET). While Ga- or Al[F]F-labeled FAP inhibitors (FAPIs) have been characterized in detail, the potential advantages of FAPIs containing a covalently bound F-label remain largely unknown. The aim of the present work was to address this gap by comparing two FAPIs with a covalently bound F-label and the chelator-based radioligand Al[F]F-FAPI-42.
View Article and Find Full Text PDFAppl Radiat Isot
August 2025
Department of Radiology, Washington University School of Medicine, Saint Louis, Missouri, 63110, United States. Electronic address:
We report a reliable fully automated procedure to produce a promising F-18 labeled sphingosine-1-phosphate receptor 1 (S1PR1) PET ligand, 3-((2-fluoro-4-(5-(4-(2-(fluoro-F)ethoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)benzyl) (methyl)amino)propan-1-ol ([F]FZTA) on the GE TRACERlab FX2N module, using a one-pot two-step procedure following current Good Manufacturing Practices (cGMP). The MOM-protected precursor 1 was fluorinated with no-carrier-added [F]KF, catalyzed by Kryptofix 222 under heat, to afford the intermediate [F]2. After deprotecting the MOM-group on [F]2 under acidic condition, the reaction was quenched into a neutralized solution, which was then loaded on semi-preparative HPLC for purification.
View Article and Find Full Text PDF